AI Verdict
Both stocks have similar AI ratings. Review detailed metrics below.
VIVS vs AIM Fundamental Comparison
| Metric | VIVS | AIM |
|---|---|---|
| Revenue | $131,000.0 | $22,000.0 |
| Net Income | $-13.8M | $-3.0M |
| Net Margin | -10,567.2% | -13,740.9% |
| ROE | N/A | -142.3% |
| ROA | -187.4% | -35.2% |
| Current Ratio | 2.38x | 1.01x |
| Debt/Equity | N/A | 1.98x |
| EPS | $-5.35 | $-0.69 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
VIVS vs AIM: Frequently Asked Questions
Is VIVS or AIM the better stock in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), both stocks have similar ratings. VIVS is graded D (96% confidence) while AIM is graded D (96% confidence). This is not investment advice.
How does VIVS compare to AIM fundamentally?
VivoSim Labs, INC. has ROE of N/A vs AIM ImmunoTech Inc.'s -142.3%. Net margins are -10,567.2% vs -13,740.9% respectively.
Which stock pays higher dividends, VIVS or AIM?
VIVS has a dividend yield of N/A or no dividend while AIM has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in VIVS or AIM for long term?
For long-term investing, consider that VIVS has a D grade with 96% confidence, while AIM has a D grade with 96% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about VIVS vs AIM?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For VIVS vs AIM, both AIs rate them similarly based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.